In a nutshell This study reported the effectiveness and safety of longer rituximab (Rituxan) maintenance therapy schedules (more than 2 years) for the treatment of patients with relapsed or refractory (r/r) indolent (painless) non-Hodgkin lymphoma (iNHL). The data showed that maintenance for up to 2 years with rituximab after response to...
Read More
In a nutshell This study investigated different rituximab schedules in patients with follicular lymphoma (FL) and reported their long-term treatment outcomes. The data showed that rituximab treatment alone on a standard schedule improves the long-term outcomes of these patients. Some background Follicular lymphoma (FL) is a type of non-Hodgkin...
Read More
In a nutshell The study evaluated the outcomes of immunoglobulin replacement (IgR) therapy in patients with B-cell non-Hodgkin lymphoma (B-NHL) and immunodeficiency, who were previously treated with rituximab (Rituxan). The authors found that IgR was safe and effective to increase serum immunoglobulins in such patients. Some background B-NHL happens...
Read More
In a nutshell This study looked at the quality of life for patients with advanced follicular lymphoma (FL) who were treated with obinutuzumab (Gazyva) and chemotherapy compared to those treated with rituximab (Rituxan) and chemotherapy. It found that both targeted antibody therapies improved quality of life for patients with advanced FL. Some background...
Read MoreIn a nutshell This study compared the safety and effectiveness of BCD-020 (biosimilar rituximab) to rituximab (Rituxan) in patients with non-Hodgkin’s lymphoma (NHL). This study found that BCD-020 was just as effective as standard rituximab, with manageable side effects. Some background Rituximab is commonly used in the treatment of NHL....
Read MoreIn a nutshell This study examined whether it is safe to switch from intravenous to subcutaneous rituximab (Rituxan) during first-line treatment of non-Hodgkin's lymphoma (NHL). The authors concluded that subcutaneous rituximab was safe and effective, and improved quality of life for patients. Some background Rituximab is a standard...
Read MoreIn a nutshell This study evaluated the outcomes of active surveillance versus upfront treatment for patients with nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL). It was found that active surveillance is effective for managing NLPHL. Some background NLPHL is a rare subtype of non-Hodgkin's lymphoma. It may be treated with intensive...
Read MoreIn a nutshell This study evaluated the outcomes of active surveillance versus upfront treatment for patients with nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL). It was found that active surveillance is effective for managing NLPHL. Some background NLPHL is a rare subtype of non-Hodgkin's lymphoma. It may be treated with intensive...
Read MoreIn a nutshell This study evaluated the safety and effectiveness of the BR (bendamustine, rituximab) regimen as a second-line treatment for patients with follicular lymphoma (FL) who had disease progression (tumor growth or spread) after chemoimmunotherapy. The study concluded that this regimen was effective in these patients. Some background...
Read MoreIn a nutshell This study evaluated the outcomes of concurrent (at the same time) combination antiretroviral therapy (cART) and chemotherapy in HIV-positive patients with non-Hodgkin’s lymphoma (NHL). This study concluded that concurrent cART with chemotherapy was well-tolerated and allowed for faster immune recovery in these patients, but did not...
Read MoreIn a nutshell This study evaluated the effectiveness of rituximab (Rituxan) maintenance therapy in patients with newly diagnosed follicular lymphoma (FL). This study concluded that this therapy improves survival outcomes in these patients. Some background For patients with early (stage 1 – 2) FL, aggressive radiotherapy or...
Read MoreIn a nutshell This study investigated whether the omission of vincristine (Oncovin) from the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) regimen affects survival in patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that omitting vincristine does not affect survival in these patients. Some background...
Read More
